Similarly, targeting TNF-α can increase the risk of tuberculosis [24]; anti-IL-23 drugs may cause hidradenitis suppurativa or arthritis; and medications, such as adalimumab (anti-TNF-α), secukinumab (anti-IL-17), and ustekinumab (anti-IL-23), can contribute to the development of thrombocytopenia [[25], [26], [27]]. Here, TNF is linked to arthritic joint disease.